Brandywine Global Investment Management LLC Sells 2,533 Shares of Cencora, Inc. $COR

Brandywine Global Investment Management LLC trimmed its position in shares of Cencora, Inc. (NYSE:COR) by 1.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 133,773 shares of the company’s stock after selling 2,533 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Cencora were worth $45,182,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of COR. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC purchased a new position in Cencora in the 4th quarter worth approximately $27,000. Archer Investment Corp lifted its position in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the last quarter. IAG Wealth Partners LLC bought a new stake in Cencora in the third quarter valued at approximately $30,000. Finally, Caitlin John LLC purchased a new stake in shares of Cencora during the third quarter valued at approximately $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.0%

Shares of COR opened at $274.94 on Monday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The firm’s 50-day moving average price is $292.70 and its 200-day moving average price is $330.31. The firm has a market capitalization of $53.49 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 1.48 and a beta of 0.59.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the business earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Analyst Upgrades and Downgrades

COR has been the topic of several analyst reports. Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. William Blair assumed coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. Barclays boosted their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Finally, Citigroup dropped their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.